Bristol Myers Squibb Company
NEWS
Pfizer with Headlands Research plans to launch new clinical trial sites in areas that have highly diverse populations.
The FDA has a few target action dates for the end of the month, although PDUFA dates can sometimes seem like a moving target.
Germany-based Evotec AG forged its third partnership in May, a deal with Spain’s Almirall S.A. to develop new therapeutics for severe diseases of the skin.
Possibly reflecting the current Bear market, Berkshire Hathaway has walked away from its stake in both AbbVie and BMS.
Monday woes were shared by Bristol Myers Squibb and Synairgen, as their clinical trial candidates failed to perform as expected.
Genentech’s flop of its anti-TIGIT drug has cast a shadow of doubt over the numerous companies in the process of developing their own anti-TIGIT drugs.
BridgeBio announced it has signed an exclusive deal with Bristol-Myers Squibb to develop and commercialize a potential treatment for cancer.
Cullinan and Taiho announced that Taiho was acquiring Cullinan Pearl and will co-develop and co-commercialize their non-small cell lung cancer drug.
Nuvig plans to use its funding to advance its lead molecule, complete some pre-IND enabling studies and move the molecule to the clinic to begin Phase I studies.
JOBS
IN THE PRESS